Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Development of a cyclodextrin based nasal delivery system for lorazepam (CROSBI ID 144424)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Jug, Mario ; Bećirević-Laćan, Mira Development of a cyclodextrin based nasal delivery system for lorazepam // Drug development and industrial pharmacy, 34 (2008), 8; 817-826. doi: 10.1080/03639040801926063

Podaci o odgovornosti

Jug, Mario ; Bećirević-Laćan, Mira

engleski

Development of a cyclodextrin based nasal delivery system for lorazepam

A new drug delivery system containing hydroxypropyl-ß-cyclodextrin (HP-ß-CD) and a mucoadhesive polymer was developed with the aim to overcome the limitations connected with the nasal application of drugs with low water solubility. Lorazepam, free or as cyclodextrin inclusion complex, was loaded into mucoadhesive microparticles by spray drying, using hydroxypropylmethylcellulose (HPMC), carbomer and HPMC/carbomer interpolymer complex (IPC) as mucoadhesive components. DSC analysis indicated the presence of drug crystalline areas in microparticles loaded with free lorazepam, while in those loaded with HP-ß-CD inclusion complex, the drug was amorphous. Zeta potential measurement revealed that the polymer was the main component on the surface of the microparticles. The swelling rate and mucoadhesive properties of the microparticles were determined by the polymer type used in formulation. IPC and carbomer based microparticles shoved superior swelling rate and mucoadhesion compared to the HPMC based microparticles (P<0.05). Drug loading into the polymer matrix decreased the swelling rate as well as the mucoadhesive properties of microparticles (P<0.05), while the presence of HP-ß-CD in the matrix did not induce any additional reduction of those parameters (P>0.05). The in vitro dissolution studies demonstrated that the microparticles containing the lorazepam inclusion complex displayed 1.8 - 2.5 times faster drug release compared to those containing free lorazepam. The change in the drug release rate could be connected with improved drug solubility inside the polymer matrix due to inclusion complex formation, as well as to the reduction in crystallinity following complexation, as confirmed by DSC studies.

Lorazepam; Hydroxypropyl-ß-cyclodextrin; Mucoadhesion; Nasal delivery

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

34 (8)

2008.

817-826

objavljeno

0363-9045

10.1080/03639040801926063

Povezanost rada

Farmacija

Poveznice
Indeksiranost